Increased Regulatory T-Cell Percentage Contributes to Poor CD4+ Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy

Julien Saison,1,2,3,4 Delphine Maucort Boulch,2,3,6 Christian Chidiac,2,3,4 Julie Demaret,1 Christophe Malcus,1 Laurent Cotte,2 Françoise Poitevin-Later,1 Patrick Mialhès,2 Fabienne Venet,1,3 Mary Anne Trabaud,7 Guillaume Monneret,1,3 and Tristan Ferry2,3,4; on behalf of the Lyon HIV Cohort Study

1Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, France; 2Infectious and Tropical Disease Unit, Lyon-1 University, 3Centre International de Recherche en Infectiologie, Centre CNRS U1111 (INSERM), 4UMR508, ENS de Lyon, UCB1, 5Service de Biostatistique, Hospices Civils de Lyon, 6Equipe Biostatistique Santé CNRS UMR 5558, Villeurbanne, and 7Virology Laboratory, Hospices Civils de Lyon, Hôpital Croix-Rousse, France

Background. The primary aim of this study was to determine the impact of regulatory T cells (Tregs) percentage on immune recovery in human immunodeficiency virus (HIV)-infected patients after antiretroviral therapy introduction.

Methods. A 2-year prospective study was conducted in HIV-1 chronically infected naive patients with CD4 count <500 cells/mm3. Regulatory T cells were identified as CD4+CD25highCD127low cells among CD4+ lymphocytes. Effect of Treg percentage at inclusion on CD4 evolution overtime was analyzed using a mixed-effect Poisson regression for count data.

Results. Fifty-eight patients were included (median CD4 = 293/mm3, median Treg percentage = 6.1%). Percentage of Treg at baseline and CD4 nadir were independently related to the evolution of CD4 absolute value according to time: (1) at any given nadir CD4 count, 1% increase of initial Treg was associated with a 1.9% lower CD4 absolute value at month 24; (2) at any given Treg percentage at baseline, 10 cell/mm3 increase of CD4 nadir was associated with a 2.4% increase of CD4 at month 24; and (3) both effects did not attenuate with time. The effect of Treg at baseline on CD4 evolution was as low as the CD4 nadir was high.

Conclusions. Regulatory T-cell percentage at baseline is a strong independent prognostic factor of immune recovery, particularly among patients with low CD4 nadir.

Keywords. ART; immune response; immunological failure; nadir CD4; T-regulatory cells.

The mechanisms sustaining the absence of immune recovery in human immunodeficiency virus (HIV)-infected patients upon effective antiretroviral therapy (ART) remain elusive [1]. In most studies, 20 to 30 percent of patients are concerned by a discordant response to ART, depending on the definition of the immunological failure [2–5]. In patients with abnormal T lymphocytes CD4+ (CD4) count, despite virological success, an increased mortality has been shown and cardiovascular and malignant pathologies are frequently observed [6–9]. Regulatory T cells (Tregs) are known to modulate the host response to viral infections [10, 11], but their role in HIV pathogenesis is still controversial [12, 13].

Some recent cross-sectional studies highlighted the potential deleterious role of these cells in case of suboptimal gain of CD4 count [14–18]. All included patients with many years of suppressive ART and compared the clinical and immunologic characteristics of immune
responders (ie, with appropriate CD4 recovery) with nonresponders. Therefore, it was unknown whether the elevated Treg percentage observed in nonresponders was a cause or a consequence of the disease duration and CD4 loss before ART introduction. To date, no data are available concerning the impact of Treg on the evolution of CD4 count during the 2 years after ART introduction.

The aim of this study was to prospectively analyze whether Treg percentage measured at ART introduction could be independently associated with lack of immune recovery after 2 years.

MATERIALS AND METHODS

Population

We performed a 2-year prospective cohort study including chronically HIV-1-infected naive patients with CD4 count <500/mm³ who started ART between January 2011 and March 2012. Patients were included the first day of ART and observed for 2 years. The frequency of follow-up visits and immunovirological control was based on French recommendation [19]. Patients with onc hematological diseases, cancer, and/or recent history of chemotherapy or treatment with hydroxyurea were not included. The following patients were excluded during the 2-year follow-up: (1) patients lost to follow-up; (2) patients experiencing virological failure (ie, 2 successive HIV RNA above 50 cp/mL) [19]; (3) patients with lack of follow-up (ie, less than 4 biological measurements per year) to minimize the possibility of a viral load rebound between 2 measurements impacting the CD4 recovery. CD4, Treg (determined as CD4⁺CD25⁺CD127− cells), and viral load were measured at baseline and were prospectively recorded for 1 year after ART introduction. During the second year of follow-up, only CD4 count and viral load were prospectively recorded. Written informed consent was obtained from every subject, and local Ethical Committee approval was received for the study.

Routine Laboratory Assessments

Viral loads were determined after extraction of 0.6 mL plasma using the Abbott Real Time HIV-1 assay under the dedicated m2000rt version 4.0 m2000rt software 4.0 package (quantitation limit 40 HIV RNA copies/mL).

Cellular Immunophenotyping

The absolute count of CD4 and complementary expression of cell surface were assessed on fresh whole EDTA-anticoagulated peripheral blood and measured on a FC500 flow cytometer using the FC500 software version 2 (Beckman Coulter, Hialeah, FL). Lymphocytes were stained with monoclonal antibodies according to manufacturer’s recommendation: energy-coupled dye-labeled anti-CD4, phycoerythrin-labeled anti-CD127, PC5-labeled anti-CD25 (Beckman Coulter, Hialeah, FL). Regulatory T cells were determined as CD25⁺CD127− cells among total CD4⁺ lymphocytes, and results are expressed as percentages of CD4⁺CD25⁺CD127− cells out of CD4⁺ lymphocytes. A minimum number of 2000 CD4⁺ cellular events was recorded.

Statistical Analysis

Variables were described with medians, first and third quartiles for continuous variables, and counts and percentages for categorical variables. Correlations between CD4 count and Treg were explored with Spearman tests. Impact of Treg percentage on CD4 count evolution along the first 2 years after ART introduction was studied using a mixed-effect Poisson regression. All of the prospectively recorded CD4 measurements per patient were used in the model. Time was introduced as third-order polynomial. Random intercept, slope, and quadratic term for time were included to allow for subject-specific initial CD4 value, slope, and curvature of CD4 evolution through time. Age at treatment onset and nadir of CD4 (ie, the lowest value of CD4 measured before ART introduction) were considered as main confounding variables of Treg percentage and thus were studied. Nonadjusted models were fitted before mutual adjustment. Effect sizes were represented with 95% confidence interval as multiplicative factor on CD4 cell count. Interactions of Treg and CD4 nadir, respectively, with time were tested to detect time-dependent slope of those variables on CD4 count. Interaction between Treg percentage and CD4 nadir was also tested to detect the different effect of one according to the level of the other one. Those interactions were kept in the model when P value reached 10%. To illustrate the model, we considered patients according to the level of immunosuppression (nadir CD4< or >350/mm³) and Treg percentage (< or >9%). These values approximately correspond to the top quartile of participants based on the CD4 nadir and Treg percentage distribution (Table 1). Results were considered to be significant when P values were less than 5%. Analyses were performed with R software (software 3.0.2, 2013; R Development Core Team, R: A Language Environment for Statistical Computing, Vienna, Austria).

RESULTS

Population Description

One hundred one patients were included, and 43 patients were excluded during the follow-up (Figure 1). Finally, 58 patients were observed for 26.2 months (interquartile range [IQR], 24.5–27.3). Characteristics of the population are described in Table 1. Six patients were Centers for Disease Control and Prevention (CDC) Stage C (10%), 10 CDC B (17%), and 42 CDC A (73%). Median zenith viral load was 4.7 (IQR, 4.4–5.2). Half of the patients were infected with HIV-1 B subtype viruses (n = 30). Only 2 patients were coinfected with a hepatitis virus (hepatitis B virus [HBV] = 1, HCV = 1). All patients received a nucleoside reverse transcriptase inhibitor’s backbone
(tenofovir-emtricitabine or abacavir-lamivudine) combined with (i) a protease inhibitor’s based regimen (atazanavir, darunavir or lopinavir, all boosted with ritonavir; n = 48, 82%), or with (ii) efavirenz (n = 5, 9%), or with (iii) raltegravir (n = 5, 9%).

**Correlation Between CD4, Regulatory T Cell, and Viral Load at Antiretroviral Therapy Introduction, M12 and M24**

At ART introduction, there was a significant positive correlation between Treg percentage and HIV viral load measured at ART introduction (Spearman $\rho = 0.27; P = .04$). On the contrary, there was a significant negative correlation between Treg percentage and CD4 nadir count ($R = -0.43; P < .001$) and between Treg percentage and CD4 count ($R = -0.47; P < .001$).

At month 12, the correlation between CD4 count and Treg percentage was lost ($R = -0.33; P = .06$).

**Impact of Regulatory T-Cell Percentage on CD4 Reconstitution**

In the unadjusted models, both percentage of Treg at ART introduction and CD4 nadir were statistically related to the CD4 absolute value at baseline and during follow-up. On average, 1% increase of Treg at baseline was associated with 4.2% (95% confidence interval [CI], 5.9–2.5, $P < .001$) decrease of CD4 absolute value. Similarly, patients with 10/mm$^3$ increase of CD4 nadir had on average 5.7% higher CD4 (95% CI, 5.0–6.4; $P < .001$). There was no significant effect of age on CD4 reconstitution.

In the adjusted model, both Treg percentage at baseline and CD4 nadir were related to the evolution of CD4 absolute value overtime. At any given nadir CD4 count, for each 1% of Treg more at ART introduction, a 1.9% (95% CI, 2.9–0.8, $P < .001$) lower CD4 absolute value is expected at month 24. Likewise, at any given Treg percentage at baseline, a 10/mm$^3$ higher CD4 nadir was associated with 2.4% (95% CI, 1.8–3.0, $P < .001$) higher CD4 absolute value at month 24. For both variables, the effect on CD4 does not significantly attenuate over the 2 years of the follow-up ($P > .05$; Table 2). Regulatory T cell percentage at baseline has different effect size according to the CD4 nadir, ie, it decreased when CD4 nadir increased: the impact of 1% increase of Treg on CD4 evolution was 0.14% lower for each additional 10/mm$^3$ increase of CD4 nadir (Table 2).

Figure 2 shows that CD4 nadir >350/mm$^3$ is a strong prognostic factor of immunological recovery (there were no patients with CD4 nadir >350/mm$^3$ and Treg percentage >9%). But among patients with CD4 nadir <350/mm$^3$, patients with Treg percentage <9% at baseline had a better immunological recovery than patients with Treg >9% (Figure 2A and C).

**Table 1. Baseline Characteristics of the 58 Naive HIV-1-Infected Patients Studied**

| Variable                          | N or Median | % or 1st–3rd Quartiles |
|----------------------------------|-------------|-------------------------|
| Man (%)                          | 47 (81)     |                         |
| Men who have sex with men (%)    | 41 (70)     |                         |
| Age at baseline, in year (IQR)   | 39.9 (31.2–47.7) |                       |
| CDC stage C (%)                  | 6 (10)      |                         |
| CD4 nadir, cells/mm$^3$ (IQR)    | 267 (150–325) |                       |
| Viral Load, log$_{10}$ cp/mL (IQR)| 4.4 (3.8–5) |                         |
| Protease inhibitor base regimen (%)| 48 (83)     |                         |
| Time to viral indetectability, in days (IQR) | 103 (61–168) |                     |
| Duration of follow up, in months (IQR) | 26.2 (24.5–27.3) |                       |
| CD4, cells/mm$^3$ (IQR)          | 293 (161–375) |                       |
| Treg, cells/mm$^3$ (IQR)         | 17.5 (12.2–22) |                       |
| Treg, % of CD4 (IQR)             | 6.1 (4.6–8.7) |                         |

**Table 2. Effect Sizes From Adjusted Model Including Interactions With Time, Treg, and T Lymphocytes CD4+ (CD4) Nadir on CD4 Absolute Value**

| Variable                                           | Effect Size | 95% CI         | $P$ Value |
|----------------------------------------------------|-------------|----------------|-----------|
| Treg at baseline (per additional percent)          | 0.981       | 0.971–0.992    | <.001     |
| Interaction with time (per month)                   | 1           | 0.999–1.001    | .192      |
| CD4 nadir (per 10/mm$^3$)                          | 1.024       | 1.018–1.03     | <.001     |
| Interaction with time (per month)                   | 0.999       | 0.999–1.000    | .072      |
| Interaction of Treg with CD4 nadir (per additional percent of Treg and 10/mm$^3$ CD4 nadir) | 1.001       | 1.001–1.002    | <.001     |

Abbreviations: CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile range; N, number.
DISCUSSION

In Western countries, the discordant immunological response to ART is a very frequently encountered problem and is associated with increased risk of death or cardiovascular and malignant pathologies [2–5]. In this context, CD4 nadir is known as an important prognostic factor of CD4 count reconstitution [17, 20]. Here, we extend these results by describing, in a prospective cohort study, that Treg percentage, as CD4 nadir, was an independent predictor of low CD4 recovery despite virological success. However, we found an interaction between Treg percentage and CD4 nadir, which showed that the effect of Treg percentage was attenuated for increasing values of CD4 nadir.

Recent cross-sectional observational studies described an association between Treg percentage and immunological nonresponse to highly active ART (HAART). They included patients under suppressive ART for many years and compared clinical and immunological characteristics of immunological responders versus nonresponders. This clearly suggests that a high Treg percentage could be an important factor associated with immunological discordant response to ART. However, it was argued that the differences observed in Treg percentage between the 2 groups (patients with immune recovery vs nonresponders) in such studies only reflect differences in CD4 nadir. In fact, a strong negative correlation between Treg percentage, CD4 count, and CD4 nadir has been frequently reported in viroemic untreated patients [14, 21–24]. Thus, in other words, the complex pattern of immune dysfunctions (including increased Tregs) observed in patients with incomplete immune reconstitution could be the consequence of low CD4 nadir, not the cause [16]. This is an important limitation to these previous cross-sectional studies [14–18]. To our knowledge, only 1 prospective study evaluated the impact of Tregs in immune response to ART. Its results suggest a possible prognostic value of a high Treg percentage in immunological nonresponder patients ($r^2 = 0.17, P < .05$) [25]. However, in this study, patients were observed during 1 year but have been on suppressive ART for many years (at least 2 years), which strongly limits

**Figure 2.** CD4+ T lymphocyte count evolution in the 58 antiretroviral therapy-naive human immunodeficiency virus-1-infected patients during the 2 years after highly active antiretroviral therapy introduction. Black and gray crosses represent the CD4 value of patients; black and gray curves represent the median CD4 value in each group according to the following: (1) CD4 nadir (nadir <350/mm$^3$: n = 47, nadir >350/mm$^3$: n = 11) (A); (2) percentage of regulatory T cells (Tregs) at baseline (Treg <9%: n = 45, Tregs >9%: n = 13) (B); (3) CD4 nadir and Treg percentage (nadir >350/mm$^3$ and Treg <9%: n = 11; nadir <350/mm$^3$ and Treg >9%: n = 13, nadir <350/mm$^3$ and Treg <9%, n = 34) (C).
the interpretation of the results. More importantly, it has to be highlighted that the definition used in the literature for the immunological response to ART is highly variable. The different classic outcomes such as slope of CD4 absolute value evolution overtime [14], fixed absolute value objective, or CD4 gain at end of follow up [26–28] could be impacted by CD4 count at ART introduction and by the duration of follow-up (few months or many years). In the current study, CD4 reconstitution was analyzed using a nonlinear model. Using the mixed-effect Poisson regression for count data model used here, we were able to investigate the role of Treg and CD4 nadir on immune reconstitution without misclassifying patients in groups of immunological responder or inadequate responder. Every CD4 value recorded during the prospective follow-up was used in the model. This allowed analysis of interaction between CD4 absolute value evolution, CD4 nadir, and Treg percentage at baseline with time. Using this model, we describe a negative impact of a high Treg percentage at ART introduction on immunological response, thereby confirming results of previous cross-sectional studies [14–18]. More importantly, we highlighted that this effect does not attenuate with time.

We believe that our results are of major importance. First, Treg percentage should now be used to detect patients at risk of immunological nonresponse to ART, ie, with CD4 nadir less than 350/mm³ and Tregs of more than 9% (Figure 2). On the contrary, it is probable that patients with high CD4 nadir (whatever the Treg percentage), or with a low Treg percentage at ART introduction, have a high probability of achieving a normal reconstitution of CD4 count. Such high-risk patients (CD4 nadir <350/mm³ and Treg percentage >9%–10%) should be preferentially included in therapeutics assays, which are conducted to improve the immune response.

Second, these results raise the question of the interest of directly targeting Treg, in complement with ART, in patients with low nadir and high Treg percentages. However, the direct pathogenic role of this CD4 subset in the immunological nonresponse is not yet proven. Pion et al [29] have shown that HIV infection down regulates Foxp3 expression in Treg, which is followed by the loss of their suppressive capacity and alterations in suppressive cytokine secretion pattern. We can hypothesize that once virological suppression is obtained under ART, free-viruses/uninfected Treg could disrupt CD4 homeostasis. This has been suggested by others [15]. It would now be interesting to perform in vitro functional assays of Treg from aviremic patients under long-term ART, to compare results from immunological responders versus patients with a persistently low CD4 repopulation. If a deleterious effect is confirmed in aviremic treated patients, new therapeutics strategies targeting Treg should be elaborated, as already proposed in cancer [30, 31].

Our study has some limitations. In particular, we did not observe a statistical relationship between age and immunological response. Indeed, previous studies found that increasing age is associated with a smaller CD4 gain [4, 32]. This can probably be explained in the current study by a lack of statistical power due to the relatively low duration of ART and the low number of patients studied.

CONCLUSIONS

In conclusion, in this population of HIV-infected naive patients, a high Treg percentage measured at ART introduction was associated with a lower CD4 T cell recovery during the 2 following years. The percentage of Tregs could be used in clinical practice in association with CD4 nadir to detect patients at risk for immunological nonresponse to ART.

Acknowledgments

We thank patients and all the members of the Lyon HIV Cohort Study. Author contributions. J. S., T. F., G. M., F. V., and J. D. designed the study, performed immunological laboratory assessment, statistical analysis, and the writing of the manuscript. C. M. and F. P. performed immunological laboratory assessment. D. M. B. performed statistical analysis and the writing of the manuscript, J. S., T. F., L. C., P. M., and C. C. included patients. Financial support. This work was supported by Hospices Civils de Lyon, who received a grant from MSD France to perform the cellular immunophenotyping.

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012; 2012:670957.
2. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401–10.
3. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328–35.
4. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl. in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361–72.
5. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787–94.
6. Loufty MR, Genebat M, Moore D, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 1999 2010; 55:451–9.
7. Van Lelyveld SF, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS Lond Engl 2012; 26:465–74.
8. Engsig FN, Gerstoft J, Kronborg G, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study. BMC Infect Dis 2010; 10:318.
9. Pacheco YM, Jarrín I, Del Amo J, et al. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain
low CD4 counts, despite virological response to HAART. Curr HIV Res 2009; 7:612–9.
10. Lund JM, Haq L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008; 320:1220–4.
11. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 2008; 82:21–30.
12. Moreno-Fernandez ME, Presicce P, Chougnet CA. Homeostasis and function of regulatory T cells in HIV/SIV infection. J Virol 2012; 86:10626–9.
13. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood 2013; 121:29–37.
14. Horta A, Nobrega C, Amorim-Machado P, et al. Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4+ T cells. PloS One 2013; 8:e57336.
15. Méndez-Lagares G, Pozo-Balado MM, del Mar del Pozo Balado M, et al. Severe immune dysregulation affects CD4+CD25(high)FoxP3+ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J Infect Dis 2012; 205:1501–9.
16. Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS Lond Engl 2010; 24:1991–2000.
17. Saison J, Ferry T, Demaret J, et al. Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol 2014; 176:401–9.
18. Foxall RB, Albuquerque AS, Soares RS, et al. Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection in direct association with CD4+ T-cell depletion irrespectively of viremia. AIDS Lond Engl 2011; 25:1961–70.
19. Hoen B, Bonnet F, Delaugerre C, et al. French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. J Int AIDS Soc 2014; 17:19034.
20. Negredo E, Massanella M, Puig J, et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010; 50:1390–8.
21. Angin M, Kwon DS, Streek H, et al. Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J Infect Dis 2012; 205:1495–500.
22. Bi X, Suzuki Y, Gatanaga H, Oka S. High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol 2009; 39:301–9.
23. Lim A, Tan D, Price P, et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS Lond Engl 2007; 21:1525–34.
24. Tsuemi S, Iwasaki T, Imado T, et al. Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS Lond Engl 2005; 19:879–86.
25. Gaardbo JC, Hartling HJ, Ronit A, et al. Regulatory T cells in HIV-infected immunological nonresponders are increased in blood but depleted in lymphoid tissue and predict immunological reconstitution. J Acquir Immune Defic Syndr 1999 2014; 66:349–57.
26. Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194:29–37.
27. Wilson RJ, Man SL, Copas A, et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2010; 11:152–60.
28. Erikstrup C, Kronborg G, Lohse N, et al. T-cell dysfunction in HIV-1-infected patients with impaired recovery of CD4 cells despite suppression of viral replication. J Acquir Immune Defic Syndr 1999 2010; 53:303–10.
29. Pion M, Jaramillo-Ruiz D, Martinez A, et al. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS Lond Engl 2013; 27:2019–29.
30. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7:880–7.
31. Needham DJ, Lee JX, Beliharz MW. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006; 343:684–91.
32. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441–6.